GlaxoSmithKline plc (ADR) (GSK)
$42.28
0.14 (+0.33%)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $42.14 |
| Daily Range | $42.10 - $42.47 |
| 52-Week Range | $27.15 - $42.70 |
| Market Cap | $119.68B |
| P/E Ratio | 10.89 |
| Dividend (Yield) | 1.85 (4.40%) |
| Volume | 2,275,783 |
| Average Daily Volume | 1,714,000 |
GSK
VS S&P 500 (SPY)
How do you think GSK will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
GSK Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
GSK News and Commentary
- GlaxoSmithKline Withdraws Avodart US New Drug Application – SmartMoney
- GlaxoSmithKline:Strong Response For Pandemrix In Children 3-17 – SmartMoney
- CDC: Sees Slight Decline In H1N1 Influenza Illnesses – SmartMoney
- WHO: Mutated H1N1 Virus In Norway Sensitive To Antiviral Drugs – SmartMoney
- 4-Star Stocks Poised to Pop: Merck – The Motley Fool
- EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix – SmartMoney
- Pfizer Dodges a Bullet – The Motley Fool
- Why You Can't Afford to Miss These Stocks – The Motley Fool
- Swiss Health Body Expands Use Of Swine-Flu Vaccine Pandemrix – SmartMoney
- UPDATE: FDA Panel Votes Against Approving Xolair In Children – SmartMoney
- The Government Won't Be There for You – The Motley Fool
- VIVUS Gets a Spark – The Motley Fool
- CMED Earning Outlook – Blog at The Motley Fool
- FDA Panel Questions Dosing Levels For Novartis's Xolair – SmartMoney
- This Partnership Is Smoking! – The Motley Fool
- A Big Upgrade for Sanofi-Aventis – The Motley Fool
- Music to Health-Care Investors' Ears – The Motley Fool
- GlaxoSmithKline, Nabi Biopharmactuticals In Licensing Pact – SmartMoney
- Thinking of shorting GSK – Blog at The Motley Fool
- Abbott: Brave or Stupid? – The Motley Fool
RSS Headlines
Fool UK
